Cargando…

Endogenous antibody response to SARS-CoV-2 in patients who received monoclonal antibodies against COVID-19: A systematic review

Passive immunization with mAbs has been employed in COVID-19. We performed a systematic review of the literature assessing the endogenous humoral immune response against SARS-CoV-2 in patients treated with mAbs. Administration of mAbs in seronegative patients led to a reduction in both antibody titr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lombardi, Andrea, Azzarà, Cecilia, Renisi, Giulia, Viero, Giulia, Gori, Andrea, Bandera, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Inc. 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419441/ https://www.ncbi.nlm.nih.gov/pubmed/38013970 http://dx.doi.org/10.1016/j.clicom.2022.08.003

Ejemplares similares

Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
por: Lombardi, Andrea, et al.
Publicado: (2023)

Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine
por: Lombardi, Andrea, et al.
Publicado: (2022)

Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?
por: Azzarà, Cecilia, et al.
Publicado: (2023)

Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response
por: Kim, Paul S., et al.
Publicado: (2022)

Targeting endogenous nuclear antigens by electrotransfer of monoclonal antibodies in living cells
por: Freund, Guillaume, et al.
Publicado: (2013)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?
por: Ucciferri, Claudio, et al.
Publicado: (2023)

The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies
por: Liu, Kexin, et al.
Publicado: (2022)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
por: Lombardi, Andrea, et al.
Publicado: (2021)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
por: Goldin, Laurel, et al.
Publicado: (2021)

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
por: Tuccori, Marco, et al.
Publicado: (2020)

Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272
por: Bozzi, Giorgio, et al.
Publicado: (2021)

Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia
por: Palomba, Emanuele, et al.
Publicado: (2021)

Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report
por: Fenaux, Honorine, et al.
Publicado: (2021)

Evaluation of neonatal outcomes in COVID-19 positive mothers who received monoclonal antibodies
por: Chen, Katherine, et al.
Publicado: (2023)

Viral load decrease in SARS‐CoV‐2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents
por: Valentina, Mazzotta, et al.
Publicado: (2022)

Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes
por: Cheng, Lin, et al.
Publicado: (2021)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review
por: Lombardi, Andrea, et al.
Publicado: (2022)

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
por: Xie, Jiajia, et al.
Publicado: (2021)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Functionality of Monoclonal Antibody Therapy in SARS-CoV-2
por: Ali, Ruhma, et al.
Publicado: (2022)

Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection
por: Romani, Lorenza, et al.
Publicado: (2022)

Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection
por: Lanini, Simone, et al.
Publicado: (2022)

Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy
por: Batool, Razia, et al.
Publicado: (2023)

The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
por: Benschop, Robert J., et al.
Publicado: (2022)

The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments
por: Gupta, Akshita, et al.
Publicado: (2023)

536. Development of post acute sequelae of SARS-Cov-2 infection (long Covid) in outpatient receiving monoclonal antibodies
por: Neto, Amelia, et al.
Publicado: (2023)

Atypical myelin oligodendrocyte glycoprotein antibody–associated optic neuritis and acute demyelinating polyneuropathy after SARS-CoV-2 infection: Case report and literature review
por: Bosello, Francesca, et al.
Publicado: (2023)

Long‐term persistence of neutralizing SARS‐CoV‐2 antibodies in pets
por: Decaro, Nicola, et al.
Publicado: (2021)

Nasopharyngeal Testing among Healthcare Workers (HCWs) of a Large University Hospital in Milan, Italy during Two Epidemic Waves of COVID-19
por: Comelli, Agnese, et al.
Publicado: (2021)

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
por: Follmann, Dean, et al.
Publicado: (2023)

Characterization of a broadly cross reactive tetravalent human monoclonal antibody, recognizing conformational epitopes in receptor binding domain of SARS-CoV-2
por: Garg, Sonal, et al.
Publicado: (2022)

Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

Tear antibodies to SARS‐CoV‐2: implications for transmission
por: Selva, Kevin J, et al.
Publicado: (2021)

Evaluation of respiratory complications in a cohort of preterm infants who did not receive palivizumab monoclonal antibodies
por: Bonati, Poliana Castro de Resende, et al.
Publicado: (2022)

Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy
por: Milito, Cinzia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0j1o9fj7ikb0ac96kdo79ad1f0